RxDoctor Payments Data

Londa Aldridge

Family · Plymouth, INNPI 1750805131

Payments from drug & device makers

$460in general payments, 2019–2025

Across 31 payments — averaging $14.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$159
  • Biohaven Pharmaceuticals, Inc.$71
  • AbbVie$66
  • Insulet Corporation$40
  • Novo Nordisk$35
  • Esperion Therapeutics, Inc.$28
  • plus $61 from 4 others

What the payments were for

  • Food & beverage$460100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$460 in reported general payments places this provider in the 50th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$52,717
Medicare patients
133
Services billed
1,143

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide48$88,617
JardianceEmpagliflozin39$50,272
FarxigaDapagliflozin Propanediol20$32,187
EliquisApixaban17$28,029
Tresiba Flextouch U-100Insulin Degludec38$22,142
JanuviaSitagliptin Phosphate12$18,884
Tresiba Flextouch U-200Insulin Degludec17$9,252
Breo ElliptaFluticasone/Vilanterol13$6,932
Advair HfaFluticasone Propion/Salmeterol14$5,695
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$3,555
Insulin Lispro Kwikpen U-100Insulin Lispro15$3,116
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$3,105
Testosterone14$2,121
Omeprazole101$1,848
Levothyroxine Sodium297$1,829

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$35$88,61748 claims
GSKBreo Ellipta$159$6,93213 claims
AbbVieSynthroid$66$1,70316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 4,392 family providers in Indiana.

Other family in Plymouth

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →